not used title
not used title
For years, Kaiser Family Foundation (Kaiser) has reminded lawmakers that Americans are opposed to government “negotiation” in drug pricing should it lead to less access to medicines and destroy future innovation. Sadly, in a new poll, Kaiser is joining the partisan fray and political advocacy groups who are trying desperately to build congressional support for government price-setting.
Here’s our take at PhRMA:
“It’s unfortunate when a respected organization is compelled to put out a misleading poll that contradicts years of its own nonpartisan research. This poll doesn’t present the whole debate and relies on straw-man arguments to steer the public toward a desired outcome. As Kaiser has shown for years, the public overwhelmingly rejects government price-setting when they learn it threatens access to medicines and future innovation. That’s the reality, no matter how uncomfortable it may now be for Kaiser and certain lawmakers, and that’s why patients and other concerned advocates will continue to call on Congress to reject this approach and work on a solution that lowers costs without jeopardizing access and future new treatments.”
While it has long been a trusted voice on important health care policies, Kaiser’s advocacy for this particular partisan policy outcome is deeply flawed and disappointing. Here’s why:
Kaiser has abandoned the nonpartisan, objective approach it’s always used and instead mimics political advocacy organizations. The obvious bias is to frame the argument as “supporters” versus “opponents,” while also providing unbalanced arguments on each side. For example, here’s how Protect Our Care – a group that supports government price-setting – frames the debate:
And here’s how Kaiser now frames the issue (spoiler alert: it sounds very similar):
When it has taken a more objective approach, Kaiser has consistently shown that the public OPPOSES government “negotiations” after they learn about the tradeoffs. Trusted public opinion research firms have found that to be true, and so has Kaiser – repeatedly. In fact, here is Kaiser in 2019:
And here’s Kaiser just six months ago:
Kaiser’s claim that they are presenting “the entirety of the public debate” falls flat. This latest poll does NOT present concerns over access, which as we all know is another key tradeoff the public is not willing to make. In fact, Kaiser’s own data (see here and here) shows strong public opposition to government negotiation if it could limit access to new medicines – opposition that stretches across party lines. If they were presenting the entire debate, why did Kaiser strip access concerns from its latest poll? Perhaps a better question: What is Kaiser Family Foundation really up to?
Brian Newell
is Deputy Vice President of Public Affairs at PhRMA and serves as lead spokesperson for national media. Before joining PhRMA in 2020, he served as managing director of strategic communications for the Biotechnology Innovation Organization (BIO). Prior to BIO, Brian worked on Capitol Hill for ten years, including roles on the Education and Workforce Committee, the House Republican Conference and the Ways and Means Committee. Brian graduated with a BA in Political Science from the University of Maine, his home state. He enjoys spending time with his wife and two children – especially summer vacations on the lake in Maine.
Brian Newell
What AARP isn’t telling seniors about MFN
August 24, 2026
CMS proposal could discourage patient-centered innovation
August 18, 2026
Nearly 1 in 4 patients initially denied access to IRA medicines
August 6, 2026
Medicare Part D at 20: Building on a strong foundation
July 23, 2026
MFN won’t lower costs when insurers call the shots
May 8, 2026
Guest Blog: How MFN price controls could decide my health care
April 30, 2026
Survey confirms too many insured Americans face barriers to reliable health care
April 22, 2026
States should avoid repeating the IRA’s price‑setting mistakes
April 21, 2026
Insurers routinely block seniors’ access to medicines in Medicare Part D
March 18, 2026
Americans believe U.S. pharma leadership needs to be protected
February 26, 2026
MFN undermines U.S. biopharmaceutical innovation
February 25, 2026
CMS puts patients and innovation at risk with MFN
February 24, 2026
New list of selected drugs highlights growing consequences of government price setting
January 28, 2026
50-state poll says Americans are concerned that hospital markups hurt patients
January 27, 2026
Guest blog: Making the most of the Medicare Prescription Payment Plan
December 8, 2025
What seniors can expect this open enrollment
October 14, 2025
Part D premiums are going up, while choices are going down
October 8, 2025
Delivering breakthroughs and lower costs for patients
September 8, 2025
Celebrating 60 Years of Medicare
July 30, 2025
Medicare patients face higher drug costs, despite IRA promises
July 22, 2025
Medicare Part D plans initially denied medicines for more than 70% of patients in four chronic disease areas
June 16, 2025
Health care practitioners sound the alarm on middlemen-imposed barriers to patient care, need for policy change
March 13, 2025
CMS, don’t fall behind the rest of the medical community on obesity
February 14, 2025
A new administration poses new opportunities for patient access
December 17, 2024
New PES survey: Out-of-pocket costs lead key health care priorities ahead of the November election
October 30, 2024
Americans speak out on health insurance barriers and need for policy change, according to the latest Patient Experience Survey
October 28, 2024
Is CMS paying attention to the growing access barriers for Medicare patients under the IRA?
October 18, 2024
Where voters stand ahead of the election
October 16, 2024
Did the administration consider the importance of blood cancer medicines to patients in price setting process?
October 8, 2024
Did the administration consider the importance of blood clot medicines to patients in the price setting process?
September 25, 2024
The Inflation Reduction Act could increase costs and reduce access for millions of seniors
September 17, 2024
Are the IRA’s Part B inflation rebates lowering costs for Medicare patients? No.
September 16, 2024
Key voter insights two months from Election Day
September 10, 2024
Did the administration consider the value of innovative diabetes medicines in price setting process?
August 28, 2024
New survey: Insurers confirm IRA will reduce patient treatment options
August 20, 2024
The unintended consequences of government price setting in Medicare Part D
August 16, 2024
Don’t put the government between patients and their medicines
August 7, 2024
What is the low-income subsidy program and how is it changing?
July 31, 2024
Voters across all 50 states want state policymakers to focus on health insurance and PBM practices
July 30, 2024
Case study: How seniors could face access disruptions because of the IRA’s price setting provisions
July 22, 2024
New 50-state poll Americans want to hold health insurers and PBMs accountable for high out-of-pocket costs and other practices
July 9, 2024
PhRMA reiterates concerns with IRA price setting program, urges CMS to mitigate harm
July 3, 2024
The IRA could lead to higher out-of-pocket costs for 3.5 million Medicare patients in 2026
June 25, 2024
ICYMI: What patients care about this election year
June 24, 2024
Key election year voter insights
June 6, 2024
Critics repeat same, misleading narrative on potential “costs” of new medicines
May 7, 2024
IRA is already negatively impacting access to medicines in Part D
April 25, 2024
Insurance data: PBM reform has no material impact on premiums
April 24, 2024
ICYMI: Voter priorities this election season
April 18, 2024
New study finds insurers and PBMs increasing access restrictions in Medicare Part D
April 16, 2024
What recent rhetoric on the cost of diabetes and anti-obesity medicines gets wrong
April 9, 2024
3 Takeaways from POLITICO’s Health Care Summit
April 3, 2024
Voter insights: Four things to know
March 7, 2024
Setting the Record Straight: Comparing U.S. drug prices to those in foreign countries hurts patients
February 7, 2024
As the administration continues to falsely claim Medicare “negotiation,” keep these points in mind
February 1, 2024
New poll: Americans agree that expanding the TRIPS waiver will harm U.S. global manufacturing and innovation leadership
January 29, 2024
When it comes to the future of innovation, the ball is in policymakers’ court
January 22, 2024
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
November 6, 2023
One year to Election Day: Four voter priorities to watch
November 6, 2023
New poll shows strong bipartisan support for PBM reform
October 20, 2023
ICYMI: Government watchdog report finds patients in Medicare Part D paid billions more for medicines than insurers and PBMs
September 28, 2023
IRA threatens seniors’ access to robust treatment options
September 26, 2023
Medicare Prescription Payment Plan will benefit patients if implemented correctly
September 21, 2023
Correcting the record: IRA’s government price setting provisions are unconstitutional
September 8, 2023
IRA changes to Part D risk access to medicines
August 24, 2023
With the first list of medicines out, let’s not forget why government price setting is bad policy
August 22, 2023
One year later IRAs unintended consequences are becoming reality
August 16, 2023
AARP’s latest misleading report
August 11, 2023
New report: Hospitals mark up medicine prices 500%
August 2, 2023
read more
August 2, 2023
Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation
July 26, 2023
Three things to know from the latest Patient Experience Survey
July 20, 2023
Key considerations as Congress works towards PAHPA reauthorization
July 12, 2023
Four things for CMS to keep in mind as they implement changes to Part D
June 7, 2023
Insulin: Key Facts on Access & Affordability
May 10, 2023
4 key facts on medicine prices and spending
May 9, 2023
4 Things to know about PhRMA’s new 50-state poll
May 4, 2023
Americans want state policymakers to lower out-of-pocket costs
May 1, 2023
Three facts about health care spending
April 25, 2023
CMS guidance on IRA price setting process doubles down on bad policy
April 14, 2023
A guide to MedPAC’s Part B vote today
April 13, 2023
MedPAC proposal threatens access to medicines in Part B
April 6, 2023
CMS coverage policy is detrimental to Alzheimer’s patients
April 4, 2023
How Part B’s ASP system helps control costs for the government and seniors
March 30, 2023
Key Trends: Patient experience data reveal how insurers and middlemen impose barriers in health care
March 29, 2023
Medicare Part B spending in four points
March 28, 2023
ICYMI: Cancer death rate continues to decline due to treatment advances
January 25, 2023
Novel medicines approved in 2022 offer increased treatment options for patients
January 23, 2023
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference
January 19, 2023
Study finds hepatitis C cure saved Medicaid $15 billion
January 5, 2023
In their own words: Insured Americans support policy reforms that address access and affordability concerns
December 14, 2022
In their own words: Financial barriers exacerbate access challenges for insured Americans
December 8, 2022
Medicare Part D open enrollment and what recent changes mean for beneficiaries
November 17, 2022
New data show how insurers and middlemen shift Rx costs onto patients
November 16, 2022
In their own words: Insured Americans struggle to navigate complex coverage
October 26, 2022
Many seniors are paying more for Part D medicines than their insurer
October 18, 2022
Busting 3 Myths About Copay Coupons
October 5, 2022
Mental Illness Awareness Week – A time for reflection
October 3, 2022
Navigating the patient experience: Burdens and barriers standing between patients and their care
September 12, 2022
CMS coverage policies restrict patient access to important treatment options for Alzheimer’s disease
September 1, 2022
Making coupons count for patients at the pharmacy counter
August 25, 2022
New survey: Voters seriously concerned about fine print in reconciliation bill
August 12, 2022
Myth vs. Fact: The Senate’s latest price setting proposal
August 5, 2022
The Senate’s latest price setting proposal will undermine U.S. economic growth
August 3, 2022
Celebrating Medicare’s 57th anniversary
August 2, 2022
The Senate’s latest price setting proposal will undermine: Our health care system
July 28, 2022
Survey Says: Prescription drug prices are not fueling inflation concerns for Americans
July 22, 2022
New research shows competition driven by biosimilars helps control costs in Part B
July 19, 2022
Polling continues to show voters reject so-called Medicare “negotiation” once they learn about consequences for patients
July 12, 2022
By the Numbers: Patients lose when the government sets prices
July 8, 2022
3 things voters are concerned about when it comes to their health care coverage
July 7, 2022
Prescription drug prices are not fueling inflation
July 6, 2022
CMS coverage decision restricts access to treatments for Alzheimer’s disease
June 22, 2022
Patients support state action requiring PBMs and insurers to share savings and cap costs for medicines
June 16, 2022
New poll shows voters sounding the alarm on health insurance companies and PBMs
June 6, 2022
PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for patients
May 31, 2022
Report finds PBMs are increasingly restricting patient access to medicines
May 25, 2022
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
May 13, 2022
Annual projections from NHE compared to actual health care spending
May 5, 2022
Study finds insurance barriers disproportionately burden patients with chronic illness
May 4, 2022
Three charts show how the Medicare Part D program could be improved to work better for seniors and people with disabilities
April 27, 2022
What’s really happening when it comes to prescription drug costs
April 27, 2022
Part D 101: Three charts show how the program provides comprehensive prescription drug coverage
April 26, 2022
5 public opinion polling trends to watch
April 22, 2022
Analysis: States can help patients save nearly $1,000 annually on their medicines
April 21, 2022
New analysis confirms hospitals markup prices for oncology therapies
April 21, 2022
How standardized plans can improve patients’ access to medicines
April 18, 2022
The patient experience: Uncovering the barriers to care for insured Americans
March 28, 2022
Correcting the record: Putting medicine costs and spending in context
March 24, 2022
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
March 16, 2022
Guest Post: If we truly want to cure complex diseases, politicians should reject price setting
March 14, 2022
Veterans Affairs 101: Three charts show how the VA system differs from Medicare
March 11, 2022
If drug prices are growing below the rate of inflation, why are patients still feeling the sting at the pharmacy?
March 8, 2022
The patient experience: Insurance barriers continue to impede access to health care, especially among the country’s underserved
February 28, 2022
Government price setting leaves behind families counting on new medicines
February 23, 2022
Part B 101: Three charts show the program helps control costs for health care system and enrollees
February 18, 2022
PhRMA submits comments urging CMS to withdraw coverage proposal
February 11, 2022
340B 101: Three charts show the program maximizes hospitals’ bottom line with little consideration for patients
February 8, 2022
Government price setting won’t stop insurers from shifting costs to patients
February 2, 2022
Research and development continues long after a medicine is initially approved
February 1, 2022
It’s a new year, but sadly Congress is still pursuing flawed price setting policies
January 25, 2022
New poll of all 50 states and 435 Congressional Districts shows perils of so-called Medicare “negotiation”
January 25, 2022
CBO reaffirms our innovation ecosystem leads to improved lives, long-term savings
January 21, 2022
New study finds more than half of brand medicine spending goes to the supply chain and others
January 7, 2022
New NHE data show the true picture of health care spending
December 22, 2021
Post-approval research save lives. Why is Congress trying disincentivize it?
December 17, 2021
A price control by any other name would still put patients at risk and threaten innovation
December 9, 2021
Making medicines more affordable: Making insurance work like insurance
December 8, 2021
3 things to know about the importance of post-approval research and development
December 6, 2021
Navigating the patient experience in the time of COVID-19
December 6, 2021
Guest post: Congress should not put future innovation at risk
November 29, 2021
Insurance design barriers can impact patient adherence and can lead to poor health outcomes
November 23, 2021
What is missing in the current drug pricing plan
November 23, 2021
ICYMI: PhRMA CEO speaks at STAT Summit about government price setting
November 19, 2021
Three things to know about so-called Medicare negotiation polling
November 18, 2021
In the current health care debate, Congress has lost sight of what matters to U.S. voters
November 15, 2021
Making medicines more affordable: Modernizing Medicare
November 11, 2021
What they are saying: Government price setting for medicines is not the answer
November 4, 2021
The patient experience: Insurance design hurdles lead to access issues for too many Americans
October 28, 2021
CMS finds medication adherence saved Medicare up to 46.6B in avoided health care costs between 2013 and 2018
October 19, 2021
The patient experience: Out-of-pocket costs are driving patients affordability and access challenges
October 19, 2021
ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development
October 18, 2021
New poll shows Americans reject Medicare negotiation once they learn more about the policy
October 15, 2021
To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and health care system
October 14, 2021
New report shows 3 in 10 Americans that have insurance still face a financial barrier to care
October 7, 2021
Industry leaders discuss the impact of the drug pricing debate
September 23, 2021
Five reasons tying VA prices to Medicare Part D misses the mark
September 22, 2021
America’s biopharmaceutical companies to Congress: Government “negotiation” is the wrong approach
September 15, 2021
Recent polling misrepresents public support for Medicare “negotiation”
August 31, 2021
What they’re saying: Patient advocates want to protect Medicare from government interference
August 24, 2021
Myth vs. fact: Polling and Medicare “negotiation”
August 12, 2021
ICYMI: Event spotlights how we can make Medicare work better for patients
August 4, 2021
Celebrating Medicare’s 56th anniversary
July 30, 2021
Recognizing Hepatitis R&D on World Hepatitis Day
July 28, 2021
Government “negotiation” could have devastating consequences for Medicare enrollees
July 23, 2021
Protecting Medicare from government interference
July 21, 2021
Data shows voters strongly support protecting access to their medicines
July 15, 2021
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
July 2, 2021
Medicare “negotiation” proposals threaten Americans’ access to medicines
June 30, 2021
New reports shed light on key facts about medicines and affordability
June 8, 2021
How strengthening the biosimilar marketplace benefits patients
May 18, 2021
New polling shows Americans are sounding the alarm on the TRIPS IP waiver
May 14, 2021
Four solutions Americans support to make health care more affordable
May 13, 2021
The ABCs (and Ds) of Medicare
May 13, 2021
New report demonstrates development of new medicines relies on private sector expertise and investment
May 10, 2021
Data shows that Americans are relying on vaccines to get us through the pandemic
April 22, 2021
West Virginia becomes the first state to lower patient costs by sharing the savings
April 20, 2021
Data shows that keeping a strong biopharmaceutical industry is important to Americans
March 30, 2021
ICYMI: Bipartisan lawmakers urge new administration to oppose changes to six protected classes policy
March 11, 2021
Key excerpts: PhRMA submits comments to keep the six protected classes protected
February 19, 2021
Top five issues voters want addressed in the administration’s first 100 days
February 18, 2021
Action needed to preserve the six protected classes
February 3, 2021
Insurers shift medicine costs to patients with severe chronic illnesses
February 1, 2021
Growing trend: Increased vaccine confidence
January 28, 2021
The latest misleading “poll” on drug pricing
January 28, 2021
Election insights: Common ground areas to address Americans’ health care concerns
January 26, 2021
End of year Part D reading List
December 18, 2020